Amendment # 2 to the Clinical Trial AgreementClinical Trial Agreement • March 17th, 2021
Contract Type FiledMarch 17th, 2021This amendment to the Clinical Trial Agreement (the “Amendment”) is effective on the day of publishing in contract registry (the “Amendment Effective Date”) by and between Fakultni Nemocnice Hradec Králove with its principal office and place of business at Sokolska 581, 500 05 Hradec Králove – Novy Hradec Kralove, Czech Republic represented by Prof. Vladimir Palicka, M.D.,Ph.D., dr. h. c., Director; (“Institution”), having an employment address at Klinika Onkologie a Radioterapie, Fakultni Nemocnice Hradec Králove, Sokolska 581, 500 05 Hradec Králove – Novy Hradec Kralove, Czech Republic ("Principal Investigator”) and Exelixis, Inc. with its principal office and place of business at 1851 Harbor Bay Parkway, Alameda, California 94502, USA (“Sponsor”), each of which are also referred to herein individually as a “Party,” and collectively as the “Parties.”